🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06821399
Recruiting Observational

Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus

NCT06821399 · tracked via the Priya Life Science China tracker
Sponsor
Yufan Wang
Phase
Observational
Started
2025-02-01
Last updated
2026-04-23

Condition(s) studied

DiabetesDiabetic RetinopathyType 2 Diabetes Mellitus (T2DM)

Investigational drug(s) / intervention(s)

Fundus ExaminationMetabolomics analysis

Fundus Examination: Performing fundus photography on patients to assess the progression of diabetic retinopathy (DR).

Metabolomics analysis: Conduct metabolomics testing at enrollment.

Study summary

This study aims to integrate clinical indicators and features of fundus images, combined with metabolomics, to construct an early warning model for diabetic retinopathy (DR) in type 2 diabetes. By combining clinical indicators with metabolomics, the investigators aim to establish a precise DR typing model based on the age of diabetes onset (early-onset diabetes, late-onset diabetes) and based on the coexistence with two types of diabetic macrovascular complications. A multidisciplinary collaboration will be conducted for comprehensive management of DR to control the progression of moderate-stage DR. Cloud-based patient rooms combined with continuous glucose monitoring (CGM) will further explore the role of integrated diabetes retinopathy ward management models in the management of patients undergoing diabetes retinopathy surgery, pioneering a new model for the management of advanced DR.

Eligibility

Sex
ALL
Min age
20 Years
Max age
79 Years
Healthy volunteers
No
Inclusion Criteria: * Meets the diagnostic criteria for type 2 diabetes in the "China Type 2 Diabetes Prevention and Treatment Guidelines (2020 Edition)"; * Aged between 20 and 79 years old, without other severe underlying diseases; ③ Possesses full cognitive and literacy abilities; ④ Volunteers to participate in this study and are willing to sign an informed consent form. Exclusion Criteria: * Those who have been diagnosed with type 1 or other types of diabetes; * Those with severe cardiac, pulmonary, hepatic, or renal insufficiency; * Those with mental confusion, speech disorders, or dementia, etc.; * Those who are unable to take care of themselves, bedridden, or have mobility impairments; ⑤ Women who are breastfeeding or pregnant; * Those with a recent history of surgery, trauma, acute major vascular complications, or infectious diseases.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
The first hosptial of lanzhou university Lanzhou China Recruiting
Shanghai general hosptial Shanghai China Recruiting
The forth people's hosptial of shenyang Shenyang China Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06821399 on ClinicalTrials.gov ↗ ← All trials in China